Nineteen genomic regions have been associated with high-grade serous ovarian cancer (HGSOC). We meta-analyzed >22 million variants for 398,238 women from the Ovarian Cancer Association Consortium (OCAC), UK Biobank (UKBB) and Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA) to identify novel HGSOC susceptibility loci. Eight novel variants were associated with HGSOC risk. An interesting discovery biologically was TP53 3'-UTR SNP rs78378222-T's association with HGSOC (per-T-allele relative risk (RR) = 1.44, 95% CI:1.28-1.62, P = 1.76 × 10-9). Polygenic scores (PGS) were developed using OCAC and CIMBA data and trained on FinnGen data. The optimal PGS included 64,518 variants and was associated with an odds ratio of 1.46 (95% CI:1.37-1.54) per standard deviation when validated in the UKBB. This study represents the largest HGSOC GWAS to date - demonstrating that improvements in imputation reference panels and increased sample sizes help to identify HGSOC associated variants that previously went undetected, ultimately improving PGS which can improve personalized HGSOC risk prediction.

Adult Cancer Program Lowy Cancer Research Centre University of NSW Sydney Sydney NSW Australia

Aix Marseille Université INSERM IRD SESSTIM Marseille France

AnaNeo Therapeutics New York NY USA

Assuta Medical Center Tel Aviv Israel

Basser Center for BRCA Abramson Cancer Center University of Pennsylvania Philadelphia PA USA

BMC Faculty of Medicine University of Iceland Reykjavik Iceland

British Columbia's Ovarian Cancer Research Program BC Cancer Vancouver General Hospital and University of British Columbia Vancouver BC Canada

Cancer Epidemiology Division Cancer Council Victoria East Melbourne VIC Australia

Cancer Epidemiology Division Cancer Council Victoria Melbourne VIC Australia

Cancer Genetics and Prevention Program University of California San Francisco San Francisco CA USA

Cancer Genetics Group IPO Porto Research Center Porto Comprehensive Cancer Center Porto Portugal

Cancer Genetics Laboratory Peter MacCallum Cancer Centre Melbourne VIC Australia

Cancer Prevention and Control Program Rutgers Cancer Institute of New Jersey New Brunswick NJ USA

Cancer Research Institute Ghent Ghent Belgium

Cancer Research UK Cambridge Institute University of Cambridge Cambridge UK

Carmel Medical Center Haifa Israel

Center for Bioinformatics and Functional Genomics Cedars Sinai Medical Center Los Angeles CA USA

Center for Clinical Cancer Genetics The University of Chicago Chicago IL USA

Center for Familial Breast and Ovarian Cancer Faculty of Medicine and University Hospital Cologne University of Cologne Cologne Germany

Center for Genomic Medicine Rigshospitalet Copenhagen University Hospital Copenhagen Denmark

Center for Integrated Oncology Faculty of Medicine and University Hospital Cologne University of Cologne Cologne Germany

Center for Medical Genetics Endeavor Health Evanston IL USA

Center for Medical Genetics Ghent University Hospital Ghent Belgium

Centre for Biomedical Network Research on Rare Diseases Madrid Spain

Centre for Cancer Biomarkers CCBIO Department of Clinical Science University of Bergen Bergen Norway

Centre for Cancer Genetic Epidemiology Department of Oncology University of Cambridge Cambridge UK

Centre for Cancer Genetic Epidemiology Department of Public Health and Primary Care University of Cambridge Cambridge UK

Centre for Cancer Research The Westmead Institute for Medical Research Sydney NSW Australia

Centre for Epidemiology and Biostatistics Melbourne School of Population and Global Health University of Melbourne Melbourne VIC Australia

Centro de Investigación en Red de Enfermedades Raras Madrid Spain

Chronic Disease Epidemiology Yale School of Medicine New Haven CT USA

City of Hope Clinical Cancer Genetics Community Research Network Duarte CA USA

Clinical Cancer Epidemiology Institute of Cancer Research London UK

Clinical Cancer Research Center Aalborg University Hospital Aalborg Denmark

Clinical Genetics Guy's and St Thomas' NHS Foundation Trust London UK

Clinical Genetics Research Lab Department of Cancer Biology and Genetics Memorial Sloan Kettering Cancer Center New York NY USA

Clinical Genetics Service Department of Medicine Memorial Sloan Kettering Cancer Center New York NY USA

Clinical Genome Center Department of Clinical Research University of Southern Denmark Odense Denmark

David Geffen School of Medicine Department of Obstetrics and Gynecology University of California at Los Angeles Los Angeles CA USA

Département d'Anticipation et de Suivi des Cancers Oncogénétique Clinique Institut Paoli Calmettes Marseille France

Département de Biopathologie Centre François Baclesse Caen France

Department of Basic Sciences Shaukat Khanum Memorial Cancer Hospital and Research Centre Lahore Pakistan

Department of Biomedical Data Science Stanford University School of Medicine Stanford CA USA

Department of Biomolecular Medicine Ghent University Ghent Belgium

Department of Breast Medical Oncology University of Texas MD Anderson Cancer Center Houston TX USA

Department of Cancer Biology and Genetics Ohio State University Comprehensive Cancer Center The Ohio State University Columbus OH USA

Department of Cancer Epidemiology and Genetics Masaryk Memorial Cancer Institute Brno Czech Republic

Department of Cancer Epidemiology Moffitt Cancer Center Tampa FL USA

Department of Clinical Genetics Fox Chase Cancer Center Philadelphia PA USA

Department of Clinical Genetics Helsinki University Hospital University of Helsinki Helsinki Finland

Department of Clinical Genetics Maastricht University Medical Center Maastricht The Netherlands

Department of Clinical Genetics Odense University Hospital Odense Denmark

Department of Clinical Genetics Rigshospitalet Copenhagen University Hospital Copenhagen Denmark

Department of Clinical Medicine Aalborg University Aalborg Denmark

Department of Clinical Medicine Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark

Department of Clinical Pathology Melbourne Medical School University of Melbourne Parkville Victoria Australia

Department of Computational Biomedicine Cedars Sinai Medical Center Los Angeles CA USA

Department of Epidemiology and Population Sciences Stanford University School of Medicine Stanford University Stanford CA USA

Department of Epidemiology Colorado School of Public Health University of Colorado Aurora CO USA

Department of Epidemiology Harvard T H Chan School of Public Health Boston MA USA

Department of Epidemiology University of Michigan School of Public Health Ann Arbor MI USA

Department of Epidemiology University of Texas MD Anderson Cancer Center Houston TX USA

Department of Epidemiology University of Washington Seattle WA USA

Department of Experimental and Clinical Biomedical Sciences 'Mario Serio' Medical Genetics Unit University of Florence Florence Italy

Department of Genetics and Computational Biology QIMR Berghofer Medical Research Institute Brisbane QLD Australia

Department of Genetics and Genomic Sciences Icahn School of Medicine at Mount Sinai New York NY USA

Department of Genetics and Pathology Pomeranian Medical University Szczecin Poland

Department of Genomic Medicine National Institute for Health Research Cambridge Biomedical Research Centre University of Cambridge Cambridge UK

Department of Gynaecological Oncology Westmead Hospital Sydney NSW Australia

Department of Gynecologic Oncology Duke University Hospital Durham NC USA

Department of Gynecology and Gynecologic Oncology Kliniken Essen Mitte Essen Germany

Department of Health Science and Policy Icahn School of Medicine at Mount Sinai New York NY USA

Department of Human and Medical Genetics Faculty of Medicine Vilnius University Vilnius Lithuania

Department of Internal Medicine Division of Human Genetics Ohio State University Comprehensive Cancer Center The Ohio State University Columbus OH USA

Department of Internal Medicine Division of Medical Oncology University of Kansas Medical Center Westwood KS USA

Department of Internal Medicine Huntsman Cancer Institute University of Utah Salt Lake City UT USA

Department of Laboratory Genetics Portuguese Oncology Institute of Porto Porto Comprehensive Cancer Center Porto Portugal

Department of Laboratory Medicine and Pathology Mayo Clinic Rochester MN USA

Department of Medical Oncology Family Cancer Clinic Erasmus MC Cancer Institute Rotterdam The Netherlands

Department of Medical Oncology University Hospital of Vall d'Hebron Barcelona Spain

Department of Medicine Huntsman Cancer Institute University of Utah Salt Lake City UT USA

Department of Medicine Stanford University School of Medicine Stanford University Stanford CA USA

Department of Medicine University of California Irvine Irvine CA USA

Department of Molecular Genetics National Institute of Oncology Budapest Hungary

Department of Molecular Genetics University of Toronto Toronto ON Canada

Department of Molecular Medicine Faculty of Medicine Université Laval Québec City QC Canada

Department of Molecular Oncology BC Cancer Research Centre Vancouver BC Canada

Department of Obstetrics and Gynecology Brigham and Women's Hospital Boston MA USA

Department of Obstetrics and Gynecology Haukeland University Hospital Bergen Norway

Department of Obstetrics and Gynecology Providence Medical Center Medford OR USA

Department of Obstetrics and Gynecology University of British Columbia Vancouver BC Canada

Department of Obstetrics and Gynecology Vanderbilt University Medical Center Nashville TN USA

Department of Obstetrics Gynecology and Reproductive Biology Harvard Medical School Boston MA USA

Department of Oncology Biobank National Institute of Oncology Budapest Hungary

Department of Oncology Institute of Clinical Sciences Sahlgrenska Academy University of Gothenburg Gothenburg Sweden

Department of Oncology Mayo Clinic Rochester MN USA

Department of Pathology and Laboratory Medicine Institute of Oncology and Maria Sklodowska Curie Cancer Center Warsaw Poland

Department of Pathology and Laboratory Medicine University of British Columbia Vancouver BC Canada

Department of Pathology and Laboratory Medicine University of Kansas Medical Center Kansas City KS USA

Department of Pathology and Molecular Immunology School of Medicine and Biomedical Sciences University of Porto Porto Portugal

Department of Pathology Landspitali the National University Hospital of Iceland Reykjavik Iceland

Department of Population and Public Health Sciences Keck School of Medicine University of Southern California Los Angeles CA USA

Department of Population and Public Health Sciences University of Southern California Los Angeles CA USA

Department of Population Health Sciences Huntsman Cancer Institute University of Utah Salt Lake City UT USA

Department of Population Sciences Beckman Research Institute of City of Hope Duarte CA USA

Department of Preventive Medicine Keck School of Medicine University of Southern California Norris Comprehensive Cancer Center Los Angeles CA USA

Department of Public Health Sciences University of Virginia Charlottesville VA USA

Department of Quantitative Health Sciences Mayo Clinic College of Medicine Rochester MN USA

Department of Radiation Oncology Hannover Medical School Hannover Germany

Department of Research Cancer Registry of Norway Norwegian Institute of Public Health Oslo Norway

Department of Tumor Growth Biology N N Petrov Institute of Oncology St Petersburg Russia

Department of Women's Cancer Elizabeth Garrett Anderson Institute for Women's Health University College London London UK

Dept of OB GYN and Comprehensive Cancer Center Medical University of Vienna Vienna Austria

Deptartment of Clinical Genetics South West Thames Centre for Genomics St George's University Hospitals NHS Foundation Trust London UK

Division of Cancer and Ovarian Cancer Action Research Centre Department Surgery and Cancer Imperial College London London UK

Division of Cancer Epidemiology and Genetics National Cancer Institute Bethesda MD USA

Division of Cancer Epidemiology German Cancer Research Center Heidelberg Germany

Division of Cancer Prevention and Genetics IEO European Institute of Oncology IRCCS Milan Italy

Division of Gynecologic Oncology Department of Obstetrics and Gynecology Women's Cancer Program at the Samuel Oschin Cancer Institute Cedars Sinai Medical Center Los Angeles CA USA

Division of Gynecologic Oncology Department of Obstetrics Gynecology and Reproductive Sciences University of Pittsburgh School of Medicine Pittsburgh PA USA

Division of Gynecologic Oncology University Hospital Leuven Leuven Belgium

Division of Precision Prevention The University of Kansas Cancer Center Kansas City KS USA

Epidemiology Branch National Institute of Environmental Health Sciences NIH Research Triangle Park NC USA

Escola de Doutoramento Internacional Universidade de Santiago Santiago de Compostela Spain

Faculty of Medicine and Health The University of Sydney Sydney NSW Australia

Family Cancer Clinic The Netherlands Cancer Institute Antoni van Leeuwenhoek hospital Amsterdam The Netherlands

Fundación Pública Galega de Medicina Xenómica Santiago de Compostela Spain

Genetics Department Institut Curie Paris France

Genomic Medicine Division of Evolution and Genomic Sciences The University of Manchester Manchester Academic Health Science Centre Manchester Universities Foundation Trust St Mary's Hospital Manchester UK

Genomic Medicine North West Genomics hub Manchester Academic Health Science Centre Manchester Universities Foundation Trust St Mary's Hospital Manchester UK

Genomics Center Centre Hospitalier Universitaire de Québec Université Laval Research Center Québec City QC Canada

Gynaecology Research Unit Hannover Medical School Hannover Germany

Health Informatics Institute Morsani College of Medicine University of South Florida Tampa FL USA

Health Research Institute Fundación Jiménez Díaz University Hospital Universidad Autónoma de Madrid Madrid Spain

Hematology Oncology and Transfusion Medicine Center Oncogenetics Unit Vilnius University Hospital Santaros Clinics Vilnius Lithuania

Hereditary Cancer Genetics Group Vall d'Hebron Institute of Oncology Barcelona Spain

Hereditary Cancer Program IDIBELL Catalan Institute of Oncology Barcelona Spain

Human Genotyping Unit CeGen Spanish National Cancer Research Centre Madrid Spain

Immunology and Molecular Oncology Unit Veneto Institute of Oncology IOV IRCCS Padua Italy

Independent Laboratory of Molecular Biology and Genetic Diagnostics Pomeranian Medical University Szczecin Poland

Inserm U1331 Paris France

INSERM U1339 Paris France

INSERM UMR1245 Cancer and Brain Genomics Université de Rouen Normandie Rouen France

Institut Curie Paris France

Institute for Medical Informatics Statistics and Epidemiology University of Leipzig Leipzig Germany

Institute of Cancer Sciences University of Glasgow Glasgow UK

Institute of Human Genetics University Hospital Heidelberg Heidelberg Germany

Instituto de Investigación Sanitaria de Santiago de Compostela Complejo Hospitalario Universitario de Santiago SERGAS Santiago de Compostela Spain

Jess and Mildred Fisher Center for Hereditary Cancer and Clinical Genomics Research Georgetown University Washington DC USA

Laboratory of Hematology Oncology European Institute of Oncology IRCCS Milan Italy

Leuven Cancer Institute University of Leuven Leuven Belgium

Lombardi Comprehensive Cancer Center Georgetown University Washington DC USA

Lunenfeld Tanenbaum Research Institute Sinai Health System Toronto ON Canada

Magee Womens Hospital University of Pittsburgh School of Medicine Pittsburgh PA USA

Medical Birth Registry of Norway Norwegian Institute of Public Health Oslo Norway

Mines Paris Paris France

Molecular Diagnostics Aalborg University Hospital Aalborg Denmark

Molecular Diagnostics Laboratory INRASTES National Centre for Scientific Research 'Demokritos' Athens Greece

Molecular Genetics of Breast Cancer German Cancer Research Center Heidelberg Germany

Molecular Oncology Laboratory CIBERONC Hospital Clinico San Carlos IdISSC Madrid Spain

MRC Clinical Trials Unit at UCL Institute of Clinical Trials and Methodology University College London London UK

MRC Integrative Epidemiology Unit University of Bristol Bristol UK

N N Alexandrov Research Institute of Oncology and Medical Radiology Minsk Belarus

National Cancer Institute Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda MD USA

National Tumour Biology Laboratory National Institute of Oncology Budapest Hungary

Obstetrics and Gynecology Epidemiology Center Brigham and Women's Hospital and Harvard Medical School Boston MA USA

Parkville Familial Cancer Centre Peter MacCallum Cancer Center and the Royal Melbourne Hospital Melbourne VIC Australia

Population Health Program QIMR Berghofer Medical Research Institute Brisbane QID Australia

Precision Medicine School of Clinical Sciences at Monash Health Monash University Clayton VIC Australia

Princess Margaret Cancer Center Toronto ON Canada

ProCURE IDIBELL Catalan Institute of Oncology Barcelona Spain

ProCURE IDIBGI Catalan Institute of Oncology Girona Spain

Program in Epidemiology Division of Public Health Sciences Fred Hutchinson Cancer Center Seattle WA USA

Providence Cancer Center Medford OR USA

PSL Research University Paris France

Radboud Institute for Health Sciences Radboud University Medical Center Nijmegen The Netherlands

Roswell Park Comprehensive Cancer Center Buffalo NY USA

Sackler Faculty of Medicine Tel Aviv University Ramat Aviv Israel

Samuel Oschin Comprehensive Cancer Institute Cancer Prevention and Genetics Program Cedars Sinai Medical Center Los Angeles CA USA

School of Clinical Medicine Faculty of Medicine and Health University of NSW Sydney Sydney NSW Australia

Schools of Medicine and Public Health Division of Cancer Prevention and Control Research Jonsson Comprehensive Cancer Centre UCLA Los Angeles CA USA

Sir Peter MacCallum Department of Oncology University of Melbourne Melbourne VIC Australia

SOD Genetica Molecolare University Hospital Pisa Italy

Stanford Cancer Institute Stanford University School of Medicine Stanford University Stanford CA USA

State Research Institute Centre for Innovative Medicine Vilnius Lithuania

Technion Israel Institute of Technology Haifa Israel

The Association for Promotion of Research in Precision Medicine Haifa Israel

The Daffodil Centre The University of Sydney a joint venture with Cancer Council NSW Sydney NSW Australia

The Susanne Levy Gertner Oncogenetics Unit Chaim Sheba Medical Center Ramat Gan Israel

The University of Chicago Pritzker School of Medicine Chicago IL USA

Ufa University of Science and Technology Ufa Russia

Unit of Medical Genetics Department of Medical Oncology and Hematology Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Milan Italy

Unit of Predictive Medicine Molecular Bases of Genetic Risk Department of Experimental Oncology Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy

Université Paris Cité Paris France

University of Groningen University Medical Center Groningen Department of Genetics Groningen The Netherlands

Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute Cedars Sinai Medical Center Los Angeles CA USA

Womens Cancer Research Center Magee Womens Research Institute and Hillman Cancer Center Pittsburgh PA USA

Před aktualizací

medRxiv. 2024 Mar 04:2024.02.29.24303243. doi: 10.1101/2024.02.29.24303243. PubMed

Zobrazit více v PubMed

Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. PubMed

Prat, J. New insights into ovarian cancer pathology. PubMed DOI

Peres, L. C. et al. Invasive epithelial ovarian cancer survival by histotype and disease stage. PubMed DOI PMC

Risch, H. A. et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. PubMed DOI

Risch, H. A. et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. PubMed DOI PMC

Shaw, P. A. et al. Histopathologic features of genetically determined ovarian cancer. PubMed DOI

Zhang, S. et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. PubMed DOI

Schrader, K. A. et al. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy. PubMed DOI

Wang, Y. K. et al. Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes. PubMed DOI

Lakhani, S. R. et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. PubMed DOI

O’Mahony, D. G. et al. Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2. PubMed DOI PMC

Singh, N., McCluggage, W. G. & Gilks, C. B. High-grade serous carcinoma of tubo-ovarian origin: recent developments. PubMed DOI

Kobel, M. et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. PubMed DOI

Song, H. et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. PubMed DOI PMC

Bolton, K. L. et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. PubMed DOI PMC

Goode, E. L. et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. PubMed DOI PMC

Bojesen, S. E. et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. PubMed DOI PMC

Permuth-Wey, J. et al. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. PubMed DOI PMC

Pharoah, P. D. et al. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. PubMed DOI PMC

Shen, H. et al. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. PubMed DOI PMC

Kuchenbaecker, K. B. et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. PubMed DOI PMC

Phelan, C. M. et al. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. PubMed DOI PMC

Couch, F. J. et al. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PubMed DOI PMC

Chen, K. et al. Genome-wide association study identifies new susceptibility loci for epithelial ovarian cancer in Han Chinese women. PubMed DOI

Kelemen, L. E. et al. Genome-wide significant risk associations for mucinous ovarian carcinoma. PubMed DOI PMC

Kar, S. P. et al. Genome-wide meta-analyses of breast, ovarian, and prostate cancer association studies identify multiple new susceptibility loci shared by at least two cancer types. PubMed DOI PMC

Lawrenson, K. et al. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. PubMed DOI PMC

Dareng, E. O. et al. Integrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions. PubMed DOI PMC

Genomes Project Consortium et al. A global reference for human genetic variation. PubMed DOI PMC

McCarthy, S. et al. A reference panel of 64,976 haplotypes for genotype imputation. PubMed DOI PMC

Taliun, D. et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. PubMed DOI PMC

Das, S. et al. Next-generation genotype imputation service and methods. PubMed DOI PMC

OCAC.

Chenevix-Trench, G. et al. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). PubMed DOI PMC

CIMBA.

Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. PubMed DOI PMC

Biobank, U.

Kurki, M. I. et al. FinnGen provides genetic insights from a well-phenotyped isolated population. PubMed DOI PMC

FinnGen.

Nagai, A. et al. Overview of the BioBank Japan project: study design and profile. PubMed DOI PMC

Japan, B.

Huang, L. et al. TOP-LD: a tool to explore linkage disequilibrium with TOPMed whole-genome sequence data. PubMed DOI PMC

Dareng, E. O. et al. Polygenic risk modeling for prediction of epithelial ovarian cancer risk. PubMed DOI PMC

Xiao, R. & Boehnke, M. Quantifying and correcting for the winner’s curse in genetic association studies. PubMed DOI PMC

Wakefield, J. A Bayesian measure of the probability of false discovery in genetic epidemiology studies. PubMed DOI PMC

Zhang, H. et al. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. PubMed DOI PMC

Stacey, S. N. et al. A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. PubMed DOI PMC

Stacey, S. N. et al. Germline sequence variants in TGM3 and RGS22 confer risk of basal cell carcinoma. PubMed DOI PMC

Stacey, S. N. et al. New basal cell carcinoma susceptibility loci. PubMed DOI PMC

Chahal, H. S. et al. Genome-wide association study identifies 14 novel risk alleles associated with basal cell carcinoma. PubMed DOI PMC

Di Giovannantonio, M. et al. Heritable genetic variants in key cancer genes link cancer risk with anthropometric traits. PubMed DOI PMC

Melin, B. S. et al. Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. PubMed DOI PMC

Egan, K. M. et al. Rare TP53 genetic variant associated with glioma risk and outcome. PubMed DOI PMC

Enciso-Mora, V. et al. Low penetrance susceptibility to glioma is caused by the TP53 variant rs78378222. PubMed DOI PMC

Wang, Z. et al. Further confirmation of germline glioma risk variant rs78378222 in TP53 and its implication in tumor tissues via integrative analysis of TCGA data. PubMed DOI PMC

Conti, D. V. et al. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. PubMed DOI PMC

Li, Y. et al. Single nucleotide variation in the TP53 3’ untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. PubMed DOI PMC

Bode, A. M. & Dong, Z. Post-translational modification of p53 in tumorigenesis. PubMed DOI

Olivier, M., Hussain, S. P., Caron de Fromentel, C., Hainaut, P. & Harris, C. C. PubMed

Levine, A. J. p53, the cellular gatekeeper for growth and division. PubMed DOI

Vogelstein, B., Lane, D. & Levine, A. J. Surfing the p53 network. PubMed DOI

Zhang, P. et al. Germline and somatic genetic variants in the p53 pathway interact to affect cancer risk, progression, and drug response. PubMed DOI PMC

Schildkraut, J. M. et al. Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. PubMed DOI PMC

GTEx.

Urbanek, M. et al. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. PubMed DOI PMC

Frandsen, C. L. B. et al. Risk of epithelial ovarian tumors among women with polycystic ovary syndrome: a nationwide population-based cohort study. PubMed DOI

Harris, H. R. et al. Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study. PubMed DOI PMC

Manichaikul, A. et al. Identification of novel epithelial ovarian cancer loci in women of African ancestry. PubMed DOI PMC

Lin, C. H. et al. Glutamate-cysteine ligase catalytic subunit as a therapeutic target in acute myeloid leukemia and solid tumors. PubMed PMC

Ogiwara, H. et al. Targeting the vulnerability of glutathione metabolism in ARID1A-deficient cancers. PubMed DOI

Wu, R. C., Wang, T. L. & Shih Ie, M. The emerging roles of ARID1A in tumor suppression. PubMed DOI PMC

Li, W. et al. A pan-cancer analysis reveals the diagnostic and prognostic role of CDCA2 in low-grade glioma. PubMed DOI PMC

Veeriah, S. et al. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. PubMed DOI PMC

Sherry, S. T., Ward, M. & Sirotkin, K. dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation. PubMed DOI

Rafnar, T. et al. Variants associating with uterine leiomyoma highlight genetic background shared by various cancers and hormone-related traits. PubMed DOI PMC

Harris, H. R. et al. Racial differences in the association of endometriosis and uterine leiomyomas with the risk of ovarian cancer. PubMed DOI PMC

Broggini, M. et al. Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients. PubMed

Schraml, P. et al. Cyclin E overexpression and amplification in human tumours. PubMed DOI

Cancer Genome Atlas Research, N Integrated genomic analyses of ovarian carcinoma. PubMed DOI PMC

Goundiam, O. et al. Histo-genomic stratification reveals the frequent amplification/overexpression of CCNE1 and BRD4 genes in non-BRCAness high grade ovarian carcinoma. PubMed DOI

Kang, E. Y. et al. CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: an Ovarian Tumor Tissue Analysis consortium study. PubMed DOI PMC

Cancer Genome Atlas, N Comprehensive molecular portraits of human breast tumours. PubMed DOI PMC

Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. PubMed DOI PMC

Jiang, Y. Z. et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. PubMed DOI

Jones, R. M. et al. Increased replication initiation and conflicts with transcription underlie Cyclin E-induced replication stress. PubMed DOI

Gallo, D. et al. CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition. PubMed DOI PMC

Lee, A. et al. Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors. PubMed DOI PMC

Lee, A. et al. Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1 updates to tumour pathology and cancer incidence. PubMed DOI PMC

Yang, X. et al. Validation of the BOADICEA model for epithelial tubo-ovarian cancer risk prediction in UK Biobank. PubMed PMC

Milne, R. L. et al. Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study. PubMed DOI PMC

Nickels, S. et al. Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. PubMed DOI PMC

Rudolph, A. et al. Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors. PubMed DOI PMC

Clyde, M. A. et al. Risk prediction for epithelial ovarian cancer in 11 United States-based case-control studies: incorporation of epidemiologic risk factors and 17 confirmed genetic loci. PubMed DOI PMC

Rudolph, A. et al. Joint associations of a polygenic risk score and environmental risk factors for breast cancer in the Breast Cancer Association Consortium. PubMed DOI PMC

Vachon, C. M. et al. Joint association of mammographic density adjusted for age and body mass index and polygenic risk score with breast cancer risk. PubMed DOI PMC

Kachuri, L. et al. Pan-cancer analysis demonstrates that integrating polygenic risk scores with modifiable risk factors improves risk prediction. PubMed DOI PMC

Kapoor, P. M. et al. Assessment of interactions between 205 breast cancer susceptibility loci and 13 established risk factors in relation to breast cancer risk, in the Breast Cancer Association Consortium. PubMed DOI PMC

Archambault, A. N. et al. Risk stratification for early-onset colorectal cancer using a combination of genetic and environmental risk scores: an international multi-center study. PubMed PMC

Wang, X. et al. Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 women. PubMed DOI PMC

Brnich, S. E. et al. Recommendations for application of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant interpretation framework. PubMed DOI PMC

Sakaue, S. et al. A cross-population atlas of genetic associations for 220 human phenotypes. PubMed DOI PMC

Gaudet, M. M. et al. Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PubMed DOI PMC

Amos, C. I. et al. The OncoArray Consortium: a network for understanding the genetic architecture of common cancers. PubMed DOI PMC

Milne, R. L. et al. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. PubMed DOI PMC

TOPMed.

Loh, P. R. et al. Reference-based phasing using the Haplotype Reference Consortium panel. PubMed DOI PMC

Howie, B., Fuchsberger, C., Stephens, M., Marchini, J. & Abecasis, G. R. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. PubMed DOI PMC

Fuchsberger, C., Abecasis, G. R. & Hinds, D. A. minimac2: faster genotype imputation. PubMed DOI PMC

Consortium, U. K. et al. The UK10K project identifies rare variants in health and disease. PubMed DOI PMC

UK10K.

Permuth-Wey, J. et al. LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. PubMed DOI PMC

Li, Y. et al. FastPop: a rapid principal component derived method to infer intercontinental ancestry using genetic data. PubMed DOI PMC

Antoniou, A. C. et al. RAD51 135G->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. PubMed DOI PMC

Barnes, D. R. et al. Evaluation of association methods for analysing modifiers of disease risk in carriers of high-risk mutations. PubMed DOI

Antoniou, A. C. et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. PubMed DOI PMC

Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. PubMed DOI PMC

Yang, J. et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. PubMed DOI PMC

Zhao, J. H. gap: genetic analysis package. DOI

Staley, J. R. et al. PhenoScanner: a database of human genotype-phenotype associations. PubMed DOI PMC

Kamat, M. A. et al. PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. PubMed DOI PMC

PhenoScanner.

PheWeb.

Vosa, U. et al. Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. PubMed DOI PMC

eQTLGen.

Udler, M. S., Tyrer, J. & Easton, D. F. Evaluating the power to discriminate between highly correlated SNPs in genetic association studies. PubMed DOI

Tyrer, J. P. et al. Improving on polygenic scores across complex traits using select and shrink with summary statistics (S4) and LDpred2. PubMed DOI PMC

Robin, X. et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. PubMed DOI PMC

Antoniou, A. C. et al. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. PubMed DOI PMC

UK, C. R.

Kuchenbaecker, K. B. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. PubMed DOI